Guardant Health’s 9.32% Plunge Despite 102.09% Volume Surge to $390M Ranks 377th in Market Activity

Guardant Health (GH) closed July 31, 2025, down 9.32% despite a 102.09% surge in trading volume to $390 million, ranking 377th in market activity. The decline followed mixed signals from its Q2 earnings, where revenue rose 31% to $232.1 million, outpacing analyst forecasts. Non-GAAP losses narrowed to $0.44 per share, better than expected, while full-year guidance was raised to $915–$925 million.

Strong performance came from oncology products, with 30% annual test volume growth and $158.7 million in revenue. The Shield colorectal cancer screening test, launched last year, generated $14.8 million in Q2, driven by 16,000 tests and inclusion in key guidelines. Pricing improvements, including a Medicare rate hike for Shield, boosted gross margins to 66%, up six points year-over-year. However, operating expenses climbed to $257.3 million, reflecting investments in sales expansion and Shield commercialization.

Strategic progress included 11 new Smart Liquid Biopsy applications for Guardant360, enhancing treatment options for oncologists. Regulatory milestones, such as FDA Breakthrough Device Designation for Shield, signaled long-term potential but raised questions about reimbursement sustainability. The biopharma segment grew 28% to $56 million, fueled by partnerships and data-sharing agreements.

The strategy of purchasing the top 500 stocks by daily trading volume and holding them for one day delivered a 166.71% return from 2022 to the present. This outperformed the benchmark return of 29.18%, generating an excess return of 137.53%. The strategy effectively captured market momentum while managing risk, as evidenced by its performance despite recent fluctuations in stock rankings and trading volumes.